BridgeBio Oncology Therapeutics is prioritizing BBO-8520 plus pembrolizumab in 2L+ KRAS G12C inhibitor-experienced NSCLC after a 75% ORR at 500 mg QD. For investors, the strategy concentrates Capital on programs BBOT says offer the highest probability of success, clearest development paths and greatest potential patient benefit, with operations funded into 2028.

Key Highlights

  • BBO-8520 monotherapy produced a 63% ORR and 100% DCR in 2L+ KRAS G12C inhibitor-naïve NSCLC patients.
  • BBOT expects BBO-11818 and BBO-10203 monotherapy data in the fourth quarter of 2026.
  • BBOT is prioritizing BBO-8520 plus pembrolizumab for 2L+ NSCLC patients previously treated with a KRAS G12C inhibitor after a 75% ORR at 500 mg once daily.
  • The combination achieved a 53% ORR across dose levels in 17 patients, while BBO-8520 monotherapy produced a 63% ORR and 100% DCR in 2L+ NSCLC patients.

BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) is prioritizing BBO-8520 with pembrolizumab for 2L+ KRAS G12C inhibitor-experienced NSCLC after the combination produced a 75% ORR at the 500 mg QD dose.

Three Programs Gain Focus

BBOT is directing resources toward BBO-8520 plus pembrolizumab in 2L+ NSCLC patients who have previously received a KRAS G12C inhibitor. The targeted disease areas include KRAS-mutant colorectal cancer and pancreatic ductal adenocarcinoma. BBOT said clinical data from all three programs supported the strategic prioritization.

BBO-8520 Shows Clinical Activity

In the ongoing ONKORAS-101 Phase 1 study, the BBO-8520 and pembrolizumab combination generated a 53% ORR across dose levels among 17 patients. At 500 mg once daily, the ORR was 75%. BBOT described the safety profile as generally tolerable and manageable, with adverse events primarily related to the gastrointestinal system and a favorable liver safety profile. BBO-8520 monotherapy in 2L+ NSCLC patients who had not received a KRAS G12C inhibitor produced a 63% ORR, or 26 of 41 patients, and a 100% DCR, or 41 of 41 patients. Among 28 patients eligible for six-month follow-up, 75%, or 21 of 28, remained on treatment beyond six months.

Cash Supports Development Timeline

The company projects that the balance will fund operations into 2028. The next stated data milestones include a BBO-11818 and BBO-10203 monotherapy update in the fourth quarter of 2026.